Major Trial Unpacks Long-Term Lung Effects of COVID-19

For the better part of four years, Australians have watched the pandemic reshape daily life, from snap lockdowns in Melbourne to quiet weekends at home in Perth. A new clinical trial now offers some of the clearest data yet on what COVID-19 does to the lungs long after the initial infection clears. Researchers followed thousands of participants across multiple countries, measuring lung capacity, oxygen transfer and respiratory symptoms at six, twelve and twenty-four months post-infection. The findings paint a more complicated picture than many clinicians had hoped for.

The study arrives at a moment when GPs from Bondi to Broome are reporting lingering coughs, breathlessness and fatigue among patients who had assumed their bout with the coronavirus was behind them. In Australia, where Medicare-subsidised spirometry has become a routine part of post-COVID assessment, the trial's detailed pulmonary metrics are already being folded into local clinical pathways. Researchers say the work helps explain why some people who tested positive in 2021 still feel buggered on the stairs today.

While headlines around the pandemic have moved on to other concerns, the respiratory legacy of SARS-CoV-2 remains a live issue for millions. The trial's authors argue that long-term pulmonary monitoring should become standard for anyone hospitalised with COVID-19, regardless of how mild the acute illness seemed. That recommendation lands differently in a sunburnt country where bushfire smoke and dust storms already place extra strain on the lungs.

How COVID-19 damages lung tissue over time

The first weeks of a SARS-CoV-2 infection often bring the familiar trio of cough, fever and fatigue, but the virus can also trigger a cascade of inflammatory events deeper in the respiratory system. Researchers have documented alveolar damage, microvascular clotting and persistent inflammation in the small airways of patients months after their positive test. The new trial confirms these changes are measurable phenomena affecting a meaningful slice of those infected, rather than outliers.

Australian respiratory physicians have long compared the post-COVID picture to the slow recovery seen after severe bushfire smoke exposure in towns like Mallacoota and Batemans Bay. Both involve inflammatory scarring and reduced gas exchange, though the underlying mechanisms differ. Where smoke injury tends to settle over twelve to eighteen months, COVID-related fibrosis can linger longer, particularly in patients who needed mechanical ventilation during the acute phase.

The trial also points to a less obvious phenomenon: silent hypoxia followed by delayed remodelling. Many participants had normal oxygen readings in the months after infection but showed reduced diffusing capacity when tested formally. That mismatch matters because patients often feel well enough to return to the footy or the cricket, only to discover their lungs are not quite back to where they were.

The trial design and who took part

The study recruited more than 4,500 adults from twelve health systems across Europe, North America and the Asia-Pacific, including a sizeable cohort from Australian teaching hospitals in Melbourne, Sydney and Adelaide. Participants were grouped by the severity of their initial illness, ranging from mild community infection to intensive care admission with mechanical ventilation. Each person underwent spirometry, body plethysmography, diffusing capacity testing and high-resolution CT imaging at set intervals.

The breadth of the cohort matters because much of the earlier literature on long-term respiratory effects relied on small samples or self-reported surveys. By tracking objective measurements over two years, the trial provides the kind of longitudinal data clinicians have been asking for. In Australia, the Murdoch Children's Research Institute and the University of Sydney both contributed patient data and imaging protocols.

One of the more interesting design choices was the inclusion of a control group of patients who tested negative but lived through the same pandemic conditions. That allowed researchers to separate the effects of the virus itself from background factors such as reduced exercise, weight gain and the chronic stress of lockdowns. The approach has been praised by local statisticians who say it sets a new benchmark for respiratory cohort studies.

Key findings on lung capacity and recovery

Roughly one in three participants who were hospitalised showed persistently reduced forced vital capacity at the twelve-month mark, while about one in five still had measurable impairment at twenty-four months. Diffusing capacity for carbon monoxide, a sensitive marker of alveolar function, was the metric slowest to recover. For those managed at home with a milder course, lung volumes largely returned to baseline within a year, although a small subset continued to report breathlessness that did not show up on standard tests.

These numbers help explain why a Melbourne tradie might feel wiped out after climbing two flights when they used to handle eight without blinking. The findings also track with what Australian physiotherapists have observed in their post-COVID pulmonary rehab clinics, where programs often run for sixteen weeks or longer. Slow, steady progress appears to be the rule rather than the exception.

The trial noted that women, older adults and those with a higher body mass index were more likely to experience prolonged lung function deficits. That pattern mirrors the broader long-COVID literature, which has consistently flagged these groups as facing slower recovery. Researchers caution that the data should not be read as a verdict of permanence, since many participants continued to improve between the twelve- and twenty-four-month assessments.

Comparing lung outcomes across variants

The summary draws on the trial's published subgroup analyses, though it should be read alongside the original paper for context. Omicron-era infections produced noticeably milder pulmonary sequelae than earlier strains, although the difference narrowed once vaccination status was accounted for. Researchers stress that the variant effect cannot be cleanly separated from the protection offered by prior immunisation, which became widespread in Australia during the same window.

For Australians who caught the virus during the towering Omicron wave of early 2022, the numbers offer cautious reassurance. For those who fell ill during Melbourne's brutal 2020 winter or Sydney's Delta surge, the picture is less rosy and underscores the value of ongoing monitoring. The takeaway is not that any one variant is harmless, but that cumulative immunity, treatment advances and earlier intervention have shifted the long-term risk profile.

What the findings mean for Australian patients

In practical terms, the trial supports what many Australian respiratory specialists have been telling their patients for years: a single normal chest X-ray or pulse oximeter reading is not enough to rule out post-COVID lung problems. Spirometry combined with diffusing capacity testing gives a more complete view and is now rebated through Medicare for eligible patients referred by a GP.

The findings also have an effect on workplace rehabilitation, particularly for industries with physically demanding roles. Mining, construction and aged care all require a level of cardiovascular fitness that can be undermined by reduced lung capacity. Employers from Kambalda to Cairns are being encouraged to treat post-COVID respiratory screening as a standard part of return-to-work planning rather than an optional extra.

Mental health is another layer worth naming, since persistent breathlessness feeds anxiety and disrupted sleep in ways that compound the physical symptoms. Pharmacists and primary care clinicians can find mental health guidance useful when respiratory recovery stalls and emotional wellbeing begins to slip.

Vaccination, reinfection and lung protection

The trial confirmed that vaccinated participants who later caught the virus had shorter hospital stays and a lower likelihood of persistent imaging abnormalities. That aligns with ATAGI's continued emphasis on booster doses for older Australians and those with risk conditions. While the vaccines were never designed to prevent every infection, their impact on the severity of lung involvement is now backed by some of the most rigorous data available.

Recent approvals of updated vaccines may further tilt the balance. The World Health Organization's endorsement of a next-generation COVID-19 vaccine for emergency use signals another step toward broader protection, particularly against evolving sublineages. Australian rollout details are still being finalised, but the therapeutic logic remains the same: reducing the acute hit to the lungs improves the odds of a full recovery down the track.

Reinfection remains a wild card, with the analysis hinting that repeat infections can add a small increment of risk for those with incomplete recovery from a first illness. That has prompted calls from some local immunologists for boosters to be timed not just by calendar but by individual exposure risk, especially during winter peaks in southern states.

Practical steps for Australians concerned about lung recovery

• Book a formal lung function assessment through your GP if you are still coughing or feeling short of breath three months after a positive test, especially if you were hospitalised.
• Ask about Medicare-rebated pulmonary rehabilitation programs in your state; many offer telehealth options for patients in regional areas from Tamworth to Townsville.
• Keep vaccinations up to date and discuss booster timing with your GP, particularly if you are over sixty-five or living with a chronic respiratory condition.
• Build aerobic exercise back into your routine gradually, with guidance from a physiotherapist or exercise physiologist who understands post-COVID pacing and breathlessness management.
• Stay alert to misinformation circulating online about COVID treatments and recovery, including reports that coronavirus hoax martial law emails are a big problem and can delay proper assessment and care.

Researchers behind the trial caution that lung recovery is rarely linear, and patients should expect plateaus as well as progress. The most encouraging signal is that even participants with significant impairment at twelve months continued to improve into the second year, suggesting the lungs retain more healing capacity than earlier follow-up studies implied. For Australians still living with the respiratory aftermath of earlier waves, that is a genuinely hopeful note.